Suppr超能文献

在一项采用清髓性疗法继以13-顺式维甲酸的随机试验中接受治疗的高危神经母细胞瘤患儿的长期结果:一项儿童肿瘤学组研究

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

作者信息

Matthay Katherine K, Reynolds C Patrick, Seeger Robert C, Shimada Hiroyuki, Adkins E Stanton, Haas-Kogan Daphne, Gerbing Robert B, London Wendy B, Villablanca Judith G

机构信息

University of California School of Medicine, 505 Parnassus Ave, Room M647, San Francisco, CA, 94143-0106, USA.

出版信息

J Clin Oncol. 2009 Mar 1;27(7):1007-13. doi: 10.1200/JCO.2007.13.8925. Epub 2009 Jan 26.

Abstract

UNLABELLED

PURPOSE We assessed the long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which patients were randomly assigned to undergo autologous purged bone marrow transplantation (ABMT) or to receive chemotherapy, and subsequent treatment with 13-cis-retinoic acid (cis-RA). PATIENTS AND METHODS Patients received the same induction chemotherapy, with random assignment (N = 379) to consolidation with myeloablative chemotherapy, total-body irradiation, and ABMT versus three cycles of intensive chemotherapy. Patients who completed consolidation without disease progression were randomly assigned to receive no further therapy or cis-RA for 6 months. Results The event-free survival (EFS) for patients randomly assigned to ABMT was significantly higher than those randomly assigned to chemotherapy; the 5-year EFS (mean +/- SE) was 30% +/- 4% versus 19% +/- 3%, respectively (P = .04). The 5-year EFS (42% +/- 5% v 31% +/- 5%) from the time of second random assignment was higher for cis-RA than for no further therapy, though it was not significant. Overall survival (OS) was significantly higher for each random assignment by a test of the log(-log(.)) transformation of the survival estimates at 5 years (P < .01). The 5-year OS from the second random assignment of patients who underwent both random assignments and who were assigned to ABMT/cis-RA was 59% +/- 8%; for ABMT/no cis-RA, it was 41% +/- 8% [corrected]; for continuing chemotherapy/cis-RA, it was 38% +/- 7%; and for chemotherapy/no cis-RA, it was 36% +/- 7%.

CONCLUSION

Myeloablative therapy and autologous hematopoietic cell rescue result in significantly better 5-year EFS than nonmyeloablative chemo therapy; neither myeloablative therapy with [corrected] autologous hematopoietic cell rescue nor cis-RA given after consolidation therapy significantly improved OS.

摘要

未标注

目的 我们评估了参加CCG - 3891研究的高危神经母细胞瘤患者的长期预后。在该研究中,患者被随机分配接受自体净化骨髓移植(ABMT)或接受化疗,随后接受13 - 顺式维甲酸(顺式RA)治疗。患者与方法 患者接受相同的诱导化疗,随机分配(N = 379)接受清髓性化疗、全身照射和ABMT巩固治疗,与接受三个周期的强化化疗。无疾病进展完成巩固治疗的患者被随机分配接受无进一步治疗或接受顺式RA治疗6个月。结果 随机分配接受ABMT的患者的无事件生存期(EFS)显著高于随机分配接受化疗的患者;5年EFS(均值±标准误)分别为30%±4%和19%±3%(P = 0.04)。从第二次随机分配时起,顺式RA组的5年EFS(42%±5%对31%±5%)高于无进一步治疗组,尽管差异无统计学意义。通过对5年生存估计值的对数(-对数(.))转换检验,每次随机分配的总生存期(OS)均显著更高(P < 0.01)。接受两次随机分配且被分配到ABMT/顺式RA的患者从第二次随机分配起的5年OS为59%±8%;ABMT/无顺式RA组为41%±8%[校正后];继续化疗/顺式RA组为38%±7%;化疗/无顺式RA组为36%±7%。

结论

清髓性治疗和自体造血细胞挽救导致5年EFS显著优于非清髓性化疗;巩固治疗后给予清髓性治疗和[校正后]自体造血细胞挽救以及顺式RA均未显著改善OS。

相似文献

7
Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):28-39. doi: 10.1016/s0360-3016(02)04506-6.
8
9
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
Lancet Oncol. 2013 Sep;14(10):999-1008. doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25.
10
High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma.
Cancer. 1991 Jul 15;68(2):242-7. doi: 10.1002/1097-0142(19910715)68:2<242::aid-cncr2820680204>3.0.co;2-p.

引用本文的文献

2
PLK4 as a Key Regulator of Neuroblastoma Differentiation and a Promising Therapeutic Target.
Int J Biol Sci. 2025 Jul 28;21(11):4979-4996. doi: 10.7150/ijbs.111449. eCollection 2025.
3
Clinical Significance of Promoter Mutations in Neuroblastoma.
JCO Precis Oncol. 2025 Jul;9:e2500074. doi: 10.1200/PO-25-00074. Epub 2025 Jul 10.
5
ALDOC promotes neuroblastoma progression and modulates sensitivity to chemotherapy drugs by enhancing aerobic glycolysis.
Front Immunol. 2025 Apr 17;16:1573815. doi: 10.3389/fimmu.2025.1573815. eCollection 2025.
7
A Comprehensive Review Exploring the Role of Bone Morphogenetic Proteins [BMP]: Biological Mechanisms.
Curr Issues Mol Biol. 2025 Feb 27;47(3):156. doi: 10.3390/cimb47030156.
8
Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma.
Front Oncol. 2025 Mar 4;15:1553511. doi: 10.3389/fonc.2025.1553511. eCollection 2025.

本文引用的文献

1
Analyzing survival curves at a fixed point in time.
Stat Med. 2007 Oct 30;26(24):4505-19. doi: 10.1002/sim.2864.
2
Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology.
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1424-31. doi: 10.1016/j.ijrobp.2005.10.020. Epub 2006 Jan 19.
4
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
J Clin Oncol. 2005 Sep 20;23(27):6459-65. doi: 10.1200/JCO.2005.05.571. Epub 2005 Aug 22.
6
Retinoid therapy of high-risk neuroblastoma.
Cancer Lett. 2003 Jul 18;197(1-2):185-92. doi: 10.1016/s0304-3835(03)00108-3.
8
Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
Br J Cancer. 2000 Nov;83(9):1121-3. doi: 10.1054/bjoc.2000.1430.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验